CEL-SCI Corp.
8229 Boone Boulevard
Suite 802
Vienna,
VA 22182
United States - Map
Phone: 703-506-9460
Fax: 703-506-9471
Web Site: http://www.cel-sci.com
| CEL-SCI Corporation engages in the research and development of drugs and vaccines used in the treatment of cancer. The companys lead product includes Multikine, which is under development for the treatment of cancer and is cleared for a Phase III clinical trial in advanced primary head and neck cancer patients. Multikine is a patented immunotherapeutic agent consisting of a mixture of naturally occurring cytokines, including interleukins, interferons, chemokines, and colony-stimulating factors. The company also develops CEL-1000, which is derived from a pre-clinical technology called Ligand Epitope Antigen Presentation System for protection for animals against avian flu, herpes, malaria, viral encephalitis, smallpox, vaccinia, and cancer, as well as CEL-2000, for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is based in Vienna, Virginia. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Geert R. Kersten Esq., 50
Chief Exec. Officer, Principal Financial Officer, Principal Accounting Officer, Treasurer |
$
424.00K |
$
0 | Mr. Maximilian De Clara , 79
Founder, Pres, Director and Member of Compensation Committee |
$
383.00K |
$
0 | Ms. Patricia B. Prichep , 57
Sr. VP of Operations and Sec. |
$
185.00K |
$
0 | Dr. Eyal Talor Ph.D, 52
Sr. VP of Research & Manufacturing |
$
229.00K |
$
0 |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.23% Nasdaq 
0.01 (0.81%) 
Profile
